Orgenesis raises $2.3M in private placement of common stock and warrants

Orgenesis Inc.

Sold 2,272,719 shares at $1.03 per share plus warrants for up to 2,272,719 shares at $1.50 and $2.00.
Gross proceeds of ~$2.3M before expenses; proceeds for general corporate purposes.
Offering closed March 5, 2024; warrants exercisable immediately, expire in 5 years.
Participation includes healthcare industry executives and physicians.
Securities sold under Regulation D exemption; not registered under Securities Act.

Key facts

Extracted from this filing and checked against the source text.

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.95

Orgenesis Inc. entered into Securities Purchase Agreement with certain accredited investors valued at approximately $2.3 million (effective 2024-03-03).

Action: entry
Agreement: equity purchase
Counterparty: certain accredited investors
Value: approximately $2.3 million
Effective: 2024-03-03

Exact text from the filing

On March 3, 2024, Orgenesis Inc. (the “Company”), entered into a Securities Purchase Agreement (the “Purchase Agreement”) with certain accredited investors (each an “Investor” and, collectively, the “Investors”), pursuant to which the Company agreed to issue and sell, in a private placement (the “Offering”), 2,272,719 shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), at a purchase price of $1.03 per share (the “Shares”) and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $1.50 per share and warrants to purchase up to 2,272,719 shares of Common Stock at an exercise price of $2.00 per share (collectively, the “Warrants”).

View on SEC.gov

632 material agreements filed in the last 30 days. Browse all material agreements →

Source: SEC EDGAR

accession 0001493152-24-009178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.